A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Latest Information Update: 04 Jul 2024
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 04 Jun 2024 Results assessing the incidence of CHIP in cfDNA from patients with solid tumors and explored its association with outcomes and adverse events from a local prospective solid tumor cohort (PREDICT-L) and two randomized trials: CCTG CO.26 in metastatic colorectal cancer and CCTG PA.7, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 09 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 20 Jan 2024 Results of pooled analysis from NCT02870920 and NCT02879318; investigating the incidence of CHIP in ctDNA from patients with gastrointestinal (GI) cancers and explored its association with outcomes and adverse events , presented at the 2024 Gastrointestinal Cancers Symposium